title: Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis.
abstract: Lipoprotein lipase (LPL) is a key enzyme in lipoprotein metabolism, and has been hypothesized to exert either pro- or anti-atherogenic effects, depending on its localization. Decreased plasma LPL activity is associated with the high triglyceride (TG);-low HDL phenotype that is often observed in patients with premature vascular disease. In contrast, in the vessel wall, decreased LPL may be associated with less lipoprotein retention due to many potential mechanisms and, therefore, decreased foam cell formation. To directly assess this hypothesis, we have distinguished between the effects of variations in plasma and/or vessel wall LPL on atherosclerosis susceptibility in apoE-deficient mice. Reduced LPL in both plasma and vessel wall (LPL(+/-)E(-/-)) was associated with increased TG and increased total cholesterol (TC) compared with LPL(+/+)E(-/-) sibs. However despite their dyslipidemia, LPL(+/-)E(-/-) mice had significantly reduced lesion areas compared to the LPL(+/+)E(-/-) mice. Thus, decreased vessel wall LPL was associated with decreased lesion formation even in the presence of reduced plasma LPL activity. In contrast, transgenic mice with increased plasma LPL but with no increase in LPL expression in macrophages, and thus the vessel wall, had decreased TG and TC and significantly decreased lesion areas compared with LPL(+/+)E(-/-) mice. This demonstrates that increased plasma LPL activity alone, in the absence of an increase in vessel wall LPL, is associated with reduced susceptibility to atherosclerosis. Taken together, these results provide in vivo evidence that the contribution of LPL to atherogenesis is significantly influenced by the balance between vessel wall protein (pro-atherogenic) and plasma activity (anti-atherogenic).
authors.affiliation: Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada V5Z 4H4.
authors.forename: S M
authors.initials: SM
authors.lastname: Clee
authors.forename: N
authors.initials: N
authors.lastname: Bissada
authors.forename: F
authors.initials: F
authors.lastname: Miao
authors.forename: L
authors.initials: L
authors.lastname: Miao
authors.forename: A D
authors.initials: AD
authors.lastname: Marais
authors.forename: H E
authors.initials: HE
authors.lastname: Henderson
authors.forename: P
authors.initials: P
authors.lastname: Steures
authors.forename: J
authors.initials: J
authors.lastname: McManus
authors.forename: B
authors.initials: B
authors.lastname: McManus
authors.forename: R C
authors.initials: RC
authors.lastname: LeBoeuf
authors.forename: J J
authors.initials: JJ
authors.lastname: Kastelein
authors.forename: M R
authors.initials: MR
authors.lastname: Hayden
mesh_terms: D000818:Animals; D001011:Aorta / Q000473:pathology; D001057:Apolipoproteins E / Q000172:deficiency / Q000235:genetics; D001161:Arteriosclerosis / Q000209:etiology*; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000201:enzymology*; D008071:Lipoprotein Lipase / Q000097:blood* / Q000235:genetics / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D008822:Mice, Transgenic; D014280:Triglycerides / Q000097:blood
chemical_list: D001057:Apolipoproteins E; D008075:Lipoproteins, HDL; D014280:Triglycerides; D008071:Lipoprotein Lipase